NCT05620914 2025-06-15
PARAMETer
Duke University
Phase 2 Withdrawn
Clinical Trials
18 trialsNCT05840770 2025-05-26
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT03925675 2024-09-03
18F-Fluciclovine PET and Multiparametric MR Imaging
Loma Linda University
Phase 2 Withdrawn
NCT05999357 2024-05-29
STRIDER
Maastricht University Medical Center
Phase 2 Withdrawn
NCT04427228 2023-08-28
MIGRAINE
University of Chicago
Phase 2 Withdrawn
NCT05255666 2023-07-11
Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
Washington University School of Medicine
Phase 2 Withdrawn
NCT04650490 2023-03-02
STICk-IM-NSCLC
Duke University
Phase 2 Withdrawn
NCT04856475 2022-03-02
NeraBrain
Jules Bordet Institute
Phase 2 Withdrawn
NCT03868423 2022-02-18
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
Ohio State University Comprehensive Cancer Center
Phase 2 Withdrawn
NCT03637868 2020-05-06
ERIBRAIN
Institut Paoli-Calmettes
Phase 2 Withdrawn
NCT02014545 2018-07-05
Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
Wake Forest University Health Sciences
Phase 2 Withdrawn
NCT01736800 2017-09-19
Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT02425072 2017-08-10
NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer
University of Kentucky
Phase 2 Withdrawn
NCT01413438 2017-07-02
Bevacizumab With or Without Surgery for Adult Glioblastomas
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT01445691 2016-05-17
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
Icahn School of Medicine at Mount Sinai
Phase 2 Withdrawn
NCT01913067 2014-07-24
CRANIAL
Jules Bordet Institute
Phase 2 Withdrawn
NCT01169116 2014-02-04
Exclusive Hypofractionated Stereotactic Radiotherapy in Non-resectable Single Brain Metastasis
Barretos Cancer Hospital
Phase 2 Withdrawn
NCT00797940 2012-12-03
CLARITY-1
Protox Inc.
Phase 2 Withdrawn